Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikko Airavaara

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2025
Gene therapy downregulating CaV1.3 reverses motor disability in aged parkinsonian male and female macaquesMikko Airavaara, Safak Er
Biochemical Society Transactions|February 16, 2023
Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's diseaseSafak Er, Mikko Airavaara
Croatian Medical Journal|May 3, 2019
Neuroprotective and reparative effects of endoplasmic reticulum luminal proteins - mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factorKatrina Albert, Mikko Airavaara
Handbook of Clinical Neurology|September 28, 2024
Viral and nonviral approachesMikko Airavaara, Mart Saarma
Pharmacology & Therapeutics|January 30, 2024
CDNF and ER stress: Pharmacology and therapeutic possibilitiesHelike Lõhelaid, Mart Saarma, Mikko Airavaara
Human Gene Therapy|July 16, 2015
Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene TherapyAndrii Domanskyi, Mart Saarma, Mikko Airavaara
Cell Transplantation|May 1, 2019
Secondary Pathology of the Thalamus after Focal Cortical Stroke in Rats is not Associated with Thermal or Mechanical Hypersensitivity and is Not Alleviated by Intra-Thalamic Post-Stroke Delivery of Recombinant CDNF or MANFJenni E Anttila, Suvi Pöyhönen, Mikko Airavaara
Frontiers in Physiology|May 21, 2019
Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and InjurySuvi Pöyhönen, Safak Er, Andrii Domanskyi, et al.
Biosensors & Bioelectronics|September 10, 2023
Real-time selective detection of dopamine and serotonin at nanomolar concentration from complex in vitro systemsSamuel Rantataro, Ilmari Parkkinen, Mikko Airavaara, et al.
Pharmacological Research|October 21, 2009
Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNSSeung T Lim, Mikko Airavaara, Brandon K Harvey
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 9, 2025
Gene therapy downregulating CaV1.3 reverses motor disability in aged parkinsonian male and female macaquesMikko Airavaara, Safak Er
Biochemical Society Transactions|February 16, 2023
Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's diseaseSafak Er, Mikko Airavaara
Croatian Medical Journal|May 3, 2019
Neuroprotective and reparative effects of endoplasmic reticulum luminal proteins - mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factorKatrina Albert, Mikko Airavaara
Handbook of Clinical Neurology|September 28, 2024
Viral and nonviral approachesMikko Airavaara, Mart Saarma
Pharmacology & Therapeutics|January 30, 2024
CDNF and ER stress: Pharmacology and therapeutic possibilitiesHelike Lõhelaid, Mart Saarma, Mikko Airavaara
Human Gene Therapy|July 16, 2015
Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene TherapyAndrii Domanskyi, Mart Saarma, Mikko Airavaara
Cell Transplantation|May 1, 2019
Secondary Pathology of the Thalamus after Focal Cortical Stroke in Rats is not Associated with Thermal or Mechanical Hypersensitivity and is Not Alleviated by Intra-Thalamic Post-Stroke Delivery of Recombinant CDNF or MANFJenni E Anttila, Suvi Pöyhönen, Mikko Airavaara
Frontiers in Physiology|May 21, 2019
Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and InjurySuvi Pöyhönen, Safak Er, Andrii Domanskyi, et al.
Biosensors & Bioelectronics|September 10, 2023
Real-time selective detection of dopamine and serotonin at nanomolar concentration from complex in vitro systemsSamuel Rantataro, Ilmari Parkkinen, Mikko Airavaara, et al.
Pharmacological Research|October 21, 2009
Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNSSeung T Lim, Mikko Airavaara, Brandon K Harvey
Pageof 10